Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-11-22T06:39:19.117Z Has data issue: false hasContentIssue false
  • English
  • Français

Lipids, thrombosis and cardiovascular disease in diabetes

Published online by Cambridge University Press:  18 April 2008

John S. Yudkin
John S. Yudkin
Affiliation:
Department of MedicineUniversity College London Medical School, G Block Archway Wing, Whittington Hospital, Archway Road, London N19 3UA
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Symposium on ‘Diabetes towards the year 2000’
Information
Proceedings of the Nutrition Society , Volume 56 , Issue 1B , March 1997 , pp. 273 - 280
Copyright
Copyright © The Nutrition Society 1997

References

REFERENCES

Ader, M. Bergman, R. N. (1994). Importance of transcapillary insulin transport to dynamics of insulin action after intravenous glucose American Journal of Physiology 266 E17–E25.Google Scholar
Anfossa, F. Chomiki, N. Alessi, M. C. Vague, P. Juhan-Vague, I. (1993). Plasminogen activator inhibitor-1 synthesis in the human hepatoma cell line Hep G2: metformin inhibits the stimulating effect of insulin Journal of Clinical Investigation 91 2185–2193.Google Scholar
Asplund-Carlson, A. Hamsten, A. Wiman, B. Carlson, L. A. (1993). Relationship between plasma plasminogen activator inhibitor-1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: studies in randomly selected normo- and hypertriglyceridaemic men Diabetologia 36 817–825.Google Scholar
Austin, M. A. (1989). Plasma triglyceride as a risk factor for coronary heart disease. The epidemiologic evidence and beyond American Journal of Epidemiology 129 249–259.Google Scholar
Austin, M. A. King, M.-C. Vranizan, K. M. Krauss, R. M. (1990). Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk Circulation 82 495–506.CrossRefGoogle ScholarPubMed
Austin, M. A. Mykkänen, L. Kuusisto, J. Edwards, K. L. Nelson, C. Haffner, S. M. Pyörälä, K. Laakso, M. (1995). Prospective study of small LDLs as a risk factor for non-insulin dependent diabetes mellitus in elderly men and women Circulation 92 1770–1778.CrossRefGoogle ScholarPubMed
Bradford Hill, A. (1965). The environment and disease: Association or causation? Proceedings of the Royal Society of Medicine 58 295–300.Google Scholar
Casscells, W. Hathor, B. David, M. Krabach, T. Vaughn, W. K. McAllister, H. A. Bearman, G. Willerson, J. T. (1996). Thermal detection of cellular infiltrates in living atherosclerotic plaques: possible implications for plaque rupture and thrombosis Lancet 347 1447–1449.Google Scholar
Chait, A. Brazg, R. L. Tribble, D. L. Krauss, R. L. (1993). Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype. pattern B American Journal of Medicine 94 351–356.CrossRefGoogle ScholarPubMed
Eckel, R. H. (1989). Lipoprotein, lipase: a multifunctional enzyme relevant to common metabolic diseases New England Journal of Medicine 320 1060–1068.Google Scholar
Feingold, K. R. Grunfeld, C. Pang, M. Doerrler, W. Krauss, R. M. (1992). LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes Arteriosclerosis and Thrombosis 12 1496–1502.Google Scholar
Folsom, A. R. Qamhieh, H. T. Wing, R. R. Jeffery, R. W. Stinson, V. L. Kuller, L. H. Wu, K. K. (1993). Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII, and other hemostatic factors in moderately overweight adults Arteriosclerosis and Thrombosis 13 162–169.Google Scholar
Fontbonne, A. Eschwége, E. Cambien, F. Richard, J.-L. Ducimetiére, P. Thibult, N. Warnet, J.-M. Claude, J.-R. Rosselin, G.-E. (1989). Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes Diabetologia 32 300–304.Google Scholar
Fuller, J. H., Shipley, M. J., Rose, G., Jarrett, R. J. & Keen, H. (1980). Coronary-heart-disease risk and impaired glucose tolerance. The Whitehall Study. Lancet i, 1373–1376.CrossRefGoogle Scholar
Gray, R. P. Patterson, D. L. H. Yudkin, J. S. (1993 a) Plasminogen activator inhibitor activity in diabetic and nondiabetic survivors of myocardial infarction Arteriosclerosis and Thrombosis 13 415–420.Google Scholar
Gray, R. P. Yudkin, J. S. Patterson, D. L. (1993 b) Enzymatic evidence of impaired reperfusion in diabetic patients after thrombolytic therapy for acute myocardial infarction: A role for plasminogen activator inhibitor? British Heart Journal 70 530–536.CrossRefGoogle ScholarPubMed
Gray, R. P. Yudkin, J. S. Patterson, D. L. H. (1993 c). Plasminogen activator inhibitor: a risk factor for myocardial infarction in diabetic subjects British Heart Journal 69 228–232.CrossRefGoogle Scholar
Haffner, S. M. Stern, M. P. Hazuda, H. P. Mitchell, B. D. Patterson, J. K. (1990). Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? Journal of the American Medical Association 263 2893–2898.Google Scholar
Hamsten, A., de Faire, U., Walldius, G., Dahlen, G., Szamosi, A., Landou, C., Blomback, M. & Wiman, B. (1987). Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet ii, 3–9.Google Scholar
Jurtan-Vague, I. Thompson, S. G. Jespersen, J. (1993). Involvement of the hemostatic system in the insulin resistance syndrome: a study of 1500 patients with angina pectoris Arteriosclerosis and Thrombosis 13 1865–1873.Google Scholar
King, G. L. Johnson, S. M. (1985). Receptor-mediated transport of insulin across endothelial cells Science 227 1583–1586.CrossRefGoogle ScholarPubMed
Laakso, M. Edieman, S. V. Brechtel, G. Baron, A. D. (1992). Impaired insulin-mediated skeletal muscle blood flow in patients with NIDDM Diabetes 41 1076–1083.Google Scholar
Laakso, M. Lehto, S. Penttilä, I. Pyörälä, K. (1993). Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes Circulation 88 1421–1430.Google Scholar
Lahdenperä, S. Sane, T. Vuorinen-Markkola, H. Knudsen, P. Taskinen, M. R. (1995). LDL particle size in mildly hypertriglyceridernic subjects: no relation to insulin resistance or diabetes Atherosclerosis 113 227–236.Google Scholar
Latron, Y. Chautan, M. Anfosso, F. Alessi, M. C. Nalbone, G. Lafont, H. Juhan-Vague, I. (1991). Stimulating effect of oxidised low density lipoprotein on plasminogen activator inhibitor-1 synthesis by endothelial cells Arteriosclerosis and Thrombosis 11 1821–1829.CrossRefGoogle ScholarPubMed
Law, M. R. Wald, N. J. Thompson, S. G. (1994). By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? British Medical Journal 308 367–372.Google Scholar
Mendall, M. A. Patel, P. Ballam, L. Strachan, D. Northfield, T. C. (1996). C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study British Medical Journal 312 1061–1065.Google Scholar
Miller, G. J. Martin, J. C. Webster, J. Wilkes, H. Miller, N. E. Wilkinson, W. H. Meade, T. W. (1986). Association between dietary fat intake and plasma factor VII coagulant activity - a predictor of cardiovascular mortality Atherosclerosis 60 269–277.CrossRefGoogle ScholarPubMed
Nagi, D. K. Hendra, T. J. Ryle, A. J. Cooper, T. M. Temple, R. C. Clark, P. M. S. Schneider, A. E. Hales, C. N. Yudkin, J. S. (1990). The relationship of concentrations of insulin, intact proinsulin and 32–33 split proinsulin with cardiovascular risk factors in type 2 (non-insulin dependent) diabetic subjects Diabetologia 33 532–537.Google Scholar
Panahloo, A. Mohamed-Ali, V. Lane, A. Green, F. Humphries, S. H. Yudkin, J. S. (1995). Determinants of plasminogen activator inhibitor-1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor-1 gene Diabetes 44 37–42.CrossRefGoogle ScholarPubMed
Panahloo, A. Yudkin, J. S. (1996). Diminished fibrinolysis in diabetes mellitus and its implication for diabetic vascular disease Coronary Artery Disease 7 723–731.CrossRefGoogle ScholarPubMed
Potter van Loon, B. J. Kluft, C. Radder, J. K. Blankenstein, M. A. Meinders, A. E. (1993). The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance Metabolism 42 945–949.CrossRefGoogle ScholarPubMed
Pyörälä, K. Pedersen, T. R. Kjekshus, J. (1995). The effect of cholesterol lowering with simvastatin on coronary events in diabetic patients with coronary heart disease Diabetes 44 Suppl. 1 35A Abstr.Google Scholar
Rosengren, A. Welin, L. Tsipogianni, A. Wilhelmsen, L. (1989). Impact of cardiovascular risk factors on coronary heart disease and mortality among middle aged diabetic men: a general population study British Medical Journal 299 1127–1131.Google Scholar
Sawdey, M. S. Loskutoff, D. J. (1991). Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo Journal of Clinical Investigation 88 1346–1353.CrossRefGoogle ScholarPubMed
Scandinavian Simvastatin Survival Study Group (1994). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 344 1383–1389.Google Scholar
Shepherd, J. Cobbe, S. M. Ford, I. Isles, C. G. Lorimer, A. R. Macfarlane, P. W. McKillop, J. H. Packard, C. J. (1995). Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia New England Journal of Medicine 333 1301–1307.Google Scholar
Stamler, J. Vaccaro, O. Neaton, J. D. Wentworth, D. For the Multiple Risk Factor Intervention Trial Research Group (1993). Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial Diabetes Care 16 434–444.Google Scholar
Steinberg, D. Parthasarathy, S. Carew, T. E. Khoo, J. C. Witztum, J. L. (1989). Modifications of low density lipoprotein that increase its atherogenicity New England Journal of Medicine 320 915–924.Google Scholar
Stewart, M. W. Laker, M. F. Dyer, R. G. Game, F. Mitcheson, J. Winocour, P. H. Alberti, K. G. M. M. (1993). Lipoprotein compositional abnormalities and insulin resistance in type II diabetic patients with mild hyperlipidemia Arteriosclerosis and Thrombosis 13 1046–1052.Google Scholar
Stiko-Rahm, A. Wiman, B. Hamsten, A. Nilsson, J. (1990). Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein cells is induced by very low density lipoprotein Arteriosclerosis 10 1067–1073.Google Scholar
Tan, K. C. B. Cooper, M. B. Ling, K. L. E. Griffin, B. A. Freeman, D. J. Packard, C. J. Shepherd, J. Hales, C. N. Betteridge, D. J. (1995). Fasting and postprandial determinants for the occurrence of small dense LDL species in non-insulin-dependent diabetic patients with and without hypertriglyceridaemia: the involvement of insulin, insulin precursor species and insulin resistance Atherosclerosis 113 273–287.CrossRefGoogle ScholarPubMed
Uusitupa, M. I. J. Niskanen, L. K. Siitonen, O. Voutilainen, E. Pyörälä, K. (1990). 5-year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level, and abnormalities in lipoprotein composition in non-insulin-dependent diabetic and nondiabetic subjects Circulation 82 27–36.CrossRefGoogle ScholarPubMed
Vague, Ph. Juhan-Vague, I. Aillaud, M. F. Badier, C. Viard, R. Alessi, M. C. Collen, D. (1986). Correlations between blood fibrinolytic activity, plasminogen activator inhibitor levels, plasma insulin and relative body weight in normal and obese subjects Metabolism 35 250–253.Google Scholar
Yudkin, J. S. (1993). How can we best prolong life? The benefits of coronary risk factor reduction in non-diabetic and diabetic subjects British Medical Journal 306 1313–1318.Google Scholar